Carfilzomib, new drug for multiple Myeloma

• Autores: José Manuel López Tricas
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 16, Nº. 4, 2014, págs. 282-288
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Evaluation of carfilzomib, an inhibitor of the proteasomic cellular system, the main system of degradation of proteins in the cells. The deciphering of the protea-some structure and mechanism of action signified a scientific breakthrough worthy of the Nobel Prize award in chemistry for its discoverers, Aaron Ciechanover, Avram Hershiko, and Irwin Rose, in 2004. Carfilzomib represents an improvement in relation to bortezomib in several aspects: specificity of action, irreversible inhibition of the proteasome system (according to initial studies) reduced incidence of peripheral neuropathy; and mainly clinical efficacy in patients who are either refractory, or have relapsed after treatment with bortezomib. Carfilzomib is indicated in mono-therapy regimen, or included in more complex treatment protocols. Carfilzomib seems to be a breakthrough for the treatment of the most complex multiple myeloma stages